Chengdu Easton Biopharmaceuticals Co Ltd (688513) - Net Assets
Based on the latest financial reports, Chengdu Easton Biopharmaceuticals Co Ltd (688513) has net assets worth CN¥2.87 Billion CNY (≈ $419.38 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.56 Billion ≈ $520.78 Million USD) and total liabilities (CN¥692.94 Million ≈ $101.40 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Chengdu Easton Biopharmaceuticals Co Ltd's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.87 Billion |
| % of Total Assets | 80.53% |
| Annual Growth Rate | 28.66% |
| 5-Year Change | 28.76% |
| 10-Year Change | 905.9% |
| Growth Volatility | 53.62 |
Chengdu Easton Biopharmaceuticals Co Ltd - Net Assets Trend (2013–2024)
This chart illustrates how Chengdu Easton Biopharmaceuticals Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Chengdu Easton Biopharmaceuticals Co Ltd (688513) total assets for the complete picture of this company's asset base.
Annual Net Assets for Chengdu Easton Biopharmaceuticals Co Ltd (2013–2024)
The table below shows the annual net assets of Chengdu Easton Biopharmaceuticals Co Ltd from 2013 to 2024. For live valuation and market cap data, see Chengdu Easton Biopharmaceuticals Co Ltd (688513) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.70 Billion ≈ $394.79 Million |
+3.63% |
| 2023-12-31 | CN¥2.60 Billion ≈ $380.96 Million |
+6.50% |
| 2022-12-31 | CN¥2.44 Billion ≈ $357.70 Million |
+6.67% |
| 2021-12-31 | CN¥2.29 Billion ≈ $335.34 Million |
+9.37% |
| 2020-12-31 | CN¥2.10 Billion ≈ $306.60 Million |
+200.42% |
| 2019-12-31 | CN¥697.44 Million ≈ $102.06 Million |
+19.80% |
| 2018-12-31 | CN¥582.19 Million ≈ $85.19 Million |
+30.75% |
| 2017-12-31 | CN¥445.28 Million ≈ $65.16 Million |
+14.24% |
| 2016-12-31 | CN¥389.79 Million ≈ $57.04 Million |
+45.33% |
| 2015-12-31 | CN¥268.21 Million ≈ $39.25 Million |
+31.96% |
| 2014-12-31 | CN¥203.25 Million ≈ $29.74 Million |
+20.54% |
| 2013-12-31 | CN¥168.62 Million ≈ $24.67 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Chengdu Easton Biopharmaceuticals Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2244.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.13 Billion | 41.84% |
| Common Stock | CN¥176.53 Million | 6.54% |
| Other Comprehensive Income | CN¥100.86 Million | 3.74% |
| Other Components | CN¥1.29 Billion | 47.88% |
| Total Equity | CN¥2.70 Billion | 100.00% |
Chengdu Easton Biopharmaceuticals Co Ltd Competitors by Market Cap
The table below lists competitors of Chengdu Easton Biopharmaceuticals Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TriCo Bancshares
NASDAQ:TCBK
|
$1.64 Billion |
|
China Publishing & Media Hldg
SHG:601949
|
$1.64 Billion |
|
Nexa Resources SA
NYSE:NEXA
|
$1.64 Billion |
|
Hefei Urban Construction Development Co Ltd
SHE:002208
|
$1.64 Billion |
|
Xiamen King Long Motor Group Co Ltd
SHG:600686
|
$1.63 Billion |
|
Bonesupport Holding AB
ST:BONEX
|
$1.63 Billion |
|
Datang Telecom Technology Co Ltd
SHG:600198
|
$1.63 Billion |
|
Systemair AB
ST:SYSR
|
$1.63 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Chengdu Easton Biopharmaceuticals Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,603,420,163 to 2,697,921,576, a change of 94,501,413 (3.6%).
- Net income of 238,234,169 contributed positively to equity growth.
- Dividend payments of 74,107,632 reduced retained earnings.
- Share repurchases of 128,993,902 reduced equity.
- Other comprehensive income increased equity by 39,574,165.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥238.23 Million | +8.83% |
| Dividends Paid | CN¥74.11 Million | -2.75% |
| Share Repurchases | CN¥128.99 Million | -4.78% |
| Other Comprehensive Income | CN¥39.57 Million | +1.47% |
| Other Changes | CN¥19.79 Million | +0.73% |
| Total Change | CN¥- | 3.63% |
Book Value vs Market Value Analysis
This analysis compares Chengdu Easton Biopharmaceuticals Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.11x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 32.88x to 4.11x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥1.92 | CN¥63.26 | x |
| 2014-12-31 | CN¥2.24 | CN¥63.26 | x |
| 2015-12-31 | CN¥2.82 | CN¥63.26 | x |
| 2016-12-31 | CN¥4.49 | CN¥63.26 | x |
| 2017-12-31 | CN¥4.98 | CN¥63.26 | x |
| 2018-12-31 | CN¥6.47 | CN¥63.26 | x |
| 2019-12-31 | CN¥5.81 | CN¥63.26 | x |
| 2020-12-31 | CN¥17.45 | CN¥63.26 | x |
| 2021-12-31 | CN¥19.08 | CN¥63.26 | x |
| 2022-12-31 | CN¥20.36 | CN¥63.26 | x |
| 2023-12-31 | CN¥21.69 | CN¥63.26 | x |
| 2024-12-31 | CN¥15.40 | CN¥63.26 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Chengdu Easton Biopharmaceuticals Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.83%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.65%
- • Asset Turnover: 0.40x
- • Equity Multiplier: 1.26x
- Recent ROE (8.83%) is below the historical average (12.88%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 9.36% | 9.07% | 0.64x | 1.62x | CN¥-1.01 Million |
| 2014 | 15.60% | 14.00% | 0.74x | 1.51x | CN¥10.50 Million |
| 2015 | 15.40% | 15.63% | 0.77x | 1.28x | CN¥13.19 Million |
| 2016 | 14.70% | 16.92% | 0.65x | 1.33x | CN¥18.34 Million |
| 2017 | 14.46% | 13.51% | 0.80x | 1.33x | CN¥19.84 Million |
| 2018 | 23.19% | 17.56% | 0.97x | 1.36x | CN¥76.80 Million |
| 2019 | 15.57% | 11.47% | 0.96x | 1.42x | CN¥38.87 Million |
| 2020 | 8.50% | 19.33% | 0.36x | 1.21x | CN¥-31.36 Million |
| 2021 | 10.14% | 22.72% | 0.37x | 1.21x | CN¥3.26 Million |
| 2022 | 10.08% | 21.06% | 0.39x | 1.23x | CN¥2.07 Million |
| 2023 | 8.70% | 20.28% | 0.33x | 1.29x | CN¥-33.77 Million |
| 2024 | 8.83% | 17.65% | 0.40x | 1.26x | CN¥-31.56 Million |
Industry Comparison
This section compares Chengdu Easton Biopharmaceuticals Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $6,387,359,426
- Average return on equity (ROE) among peers: 2.03%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Chengdu Easton Biopharmaceuticals Co Ltd (688513) | CN¥2.87 Billion | 9.36% | 0.24x | $1.63 Billion |
| Shenzhen CAU Technology Co Ltd (000004) | $948.24 Million | -53.63% | 0.17x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $7.92 Billion | 9.41% | 0.17x | $1.63 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $304.67 Million | -9.25% | 1.53x | $444.78 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $1.06 Billion | 8.06% | 0.08x | $444.44 Million |
| Chengzhi Shareholding Co Ltd (000990) | $15.52 Billion | 0.71% | 0.30x | $2.24 Billion |
| Hualan Biological EngineeringInc (002007) | $6.88 Billion | 18.64% | 0.10x | $3.87 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $428.60 Million | 11.05% | 0.37x | $1.25 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $29.65 Billion | 6.00% | 0.08x | $5.41 Billion |
| Baolingbao Biology Co Ltd (002286) | $703.11 Million | 6.09% | 0.47x | $568.58 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $1.91 Billion |
About Chengdu Easton Biopharmaceuticals Co Ltd
Chengdu Easton Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms comprising capsules, tablets, and injections, as well as active pharmaceutical ingredients (API). It also offers API products, such as Apixaban for cardiovascular applications; A… Read more